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ABSTRACT
Among the realm of highly varied vaccine perceptions 
and concerns expressed by publics around the world, 
vaccine safety is the most frequently cited. While many 
of the safety questions raised have substantial evidence 
to address the concerns, vaccines do have small risks, 
and need vigilant and responsive systems to address 
them. With more and more new vaccines, combinations 
of vaccines and new technologies to develop and deliver 
them, new safety concerns will arise that need attention. 
Adding to this landscape is the dramatic impact which 
digital communication has had on how fast rumours and 
vaccine concerns can spread, making the task of the public 
health and scientific community even more pressing. One 
of the more recently characterised vaccine safety issues, 
now named ‘immunisation stress- related- response,’ has 
gained particularly high visibility given these highly globally 
connected social media networks. To better anticipate and 
address these rapidly shared vaccine safety concerns, a 
number of global efforts and local responses are being 
made. Co- created social media campaigns engaging 
parents and adolescents have been effective, while the 
WHO’s Vaccine Safety Net (VSN) initiative has grown its 
global network to increase awareness about vaccines 
and contribute to building confidence in vaccines. The 
VSN reviews websites around the world to assess their 
quality and accuracy to ensure and promote access to 
trustworthy and science- based information on vaccine 
safety for internet users. These and the efforts of the 
multiple network partners are more crucial than ever to 
sustain public confidence in this evolving vaccine safety 
landscape.
THE STATE OF CONFIDENCE IN VACCINE SAFETY
In 2016, the Vaccine Confidence Project 
published a study on the global state of 
vaccine confidence.1 One of the core ques-
tions in the 67- country study asked whether 
respondents strongly agreed, tended to agree 
tended to disagree or strongly disagreed with 
the statement ‘vaccines are safe’. The study 
found that confidence in vaccine safety varied 
considerably across countries but was consist-
ently lower than reported confidence in the 
importance of vaccines. Other studies, too, 
have found that fear of vaccine side effects is 
one of the most frequently reported vaccine 
concerns.2 3
In 2018, the European Commission 
requested that the Vaccine Confidence Index 
used in the 67- country study, be run again in 
the 28 EU countries to be able to monitor 
any changes in sentiment. In only 2 years, 
there were already changes. Some countries 
became more confident and in others confi-
dence declined, reflecting the volatility of 
sentiment towards vaccines—and particularly 
vaccine safety. In the same year, the Wellcome 
Trust launched their first Global Monitor4 
Summary box
 ► Confidence in vaccine safety varies across coun-
tries but public confidence in safety is consistently 
lower than overall confidence in the importance of 
vaccines.
 ► The rise of internet- mediated communication 
has had a significant impact on how fast public 
safety concerns can spread, including travelling 
transnationally.
 ► Typically, emotional contagion has been studied 
within small face- to- face networks but images, vid-
eo and even text sent through social media can also 
provoke the spread of emotional states including 
psychosomatic reactions to vaccination.
 ► The Global Advisory Committee on Vaccine Safety 
has recognised the importance of the phenome-
non they have characterised as an ‘immunisation 
stress- related response’ (ISRR). This is an interplay 
of contextual issues with individual psychologi-
cal vulnerability, knowledge and preparedness for 
immunisation.
 ► Failure to differentiate between the clinical mani-
festations of ISSR—fainting, anxiety and associated 
hyperventilation following immunisation—and other 
conditions such as anaphylaxis which has resulted 
in mismanagement of cases and avoidable harm.
 ► Even when an adverse event following immunisation 
is assessed as being unrelated to the vaccine, the 
perception of a causal relationship can persist, and 
public anxieties need to be addressed.
 ► While social media has amplified fears, anxieties and 
uncertainties, social media can also be successfully 
used to listen to and engage publics in positive ways.
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study asking populations in 144 countries how they felt 
about science and health. Amidst the many questions 
related to trust, the Wellcome study included the VCI 
core questions. Consistent with the 2016 study, reported 
confidence in the safety of vaccines was consistently lower 
than confidence in the importance and effectiveness 
of vaccines. Even in Africa, where vaccine- preventable 
diseases are still a visible threat, the highest confidence in 
vaccine safety was reported in Malawi at 89%, compared 
with the even higher 95% reporting confidence in the 
importance of vaccines. Togo was the African country 
where only 33% of those surveyed agreed that vaccines 
are safe, although a much higher 72% were confident 
that vaccines are important figure 1. An even more 
recent analysis published in 2020, investigating global 
trends in vaccine confidence between 2015 and 2019, 
shows that some countries have improved in confidence 
over that time period, while others have declined. Across 
the domains of confidence in the importance, effective-
ness and safety of vaccines, safety again was the least to 
improve globally and some countries showed declining 
confidence in vaccine safety over that time period.5
SCIENTIFICALLY ASSESSED SAFETY RISKS VS RISK 
PERCEPTIONS
There is vaccine safety and there are perceptions of safety. 
There are scientific reports of adverse event following 
immunisation (AEFI) and there are socially shared 
reports of adverse events following immunisation. Both 
matter and both must be considered. Even when an AEFI 
is investigated and officially deemed to be unrelated to a 
vaccine or vaccination the perception of a causal relation-
ship between vaccination and a subsequent adverse event 
can persist and needs to be addressed. As risk expert Paul 
Slovic characterised it, there is ‘risk as analysis’ as well as 
‘risk as feelings’. He particularly points out the ‘complex 
interplay between emotion and reason that is essential to 
rational behaviour’6 In short, while reason and emotion 
are often seen as different, sometimes conflicting, 
influences on behaviour, Slovic and a growing number 
of neurologists are stressing the inter- relatedness of 
emotions and reason on health decisions and outcomes.7
While some of the public concerns and anxieties about 
vaccine safety are driven by rumours and misinforma-
tion, some of the seeds of those emotions stem from the 
reality that vaccines do have their risks, as small as they 
may seem relative to the public health benefits. And, 
when trust in government, in the local health system or 
in international stakeholders is weak, perceptions of even 
the smallest risks are amplified.8
Among the multiple safety concerns raised by different 
publics, the most recurring ones are about vaccine ingre-
dients (eg, thiomersal, adjuvants), perceptions about the 
risks of autism and autoimmune conditions resulting 
from vaccination, anxieties about too- many vaccines 
overloading the immune system, and non- specific effects 
of vaccination innovations and new technologies, such 
as the new COVID-19 vaccines using messenger RNA. In 
some of these cases, despite the available science assuring 
the safety of a particular vaccine in question, perceptions 
and anxieties about safety persist and can strongly affect 
individual and group vaccination decisions.9
Some vaccine safety questions posed by the public 
do need more scientific investigation. In May 2019, for 
instance, around 30 vaccine safety experts gathered 
at the Wellcome Trust to take a hard look at which of 
the persisting vaccine safety questions have clear scien-
tific answers, but need better communication, and 
which questions actually need more scientific studies.10 
Continuing efforts to stay on top of new questions as they 
evolve, while also continuing to be responsive to public 
concerns will be crucial moving forward.
Figure 1 Across Africa, confidence in vaccine safety is well below perceived importance.
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IMMUNISATION STRESS-RELATED RESPONSE
One of the more recently characterised vaccine safety 
issues that the Global Advisory Committee on Vaccine 
Safety (GACVS) has given more attention to is what 
they have now named as a ‘immunisation stress- related 
response’ (ISRR). WHO has introduced this new termi-
nology to describe the entire spectrum of manifestations 
(symptoms and signs) of a stress response. The biopsy-
chosocial model scientifically describes the evolution of 
ISRR in an individual through an interplay of the social 
context of immunisation with physiological factors in 
an individual interplaying with his or her psychological 
strengths as well as vulnerability, knowledge and prepar-
edness for immunisation.11 Even though stress related 
events following immunisation have been reported from 
all over the world in the last three decades,12 newer modes 
of digital media have contributed to their increased visi-
bility.13 Social media in particular has allowed new levels 
of emotional contagion around vaccines. The rise of 
internet- mediated communication has had a significant 
impact on how fast vaccine rumours and anxieties can 
spread, now travelling transnationally in and instant.
A recent study in Italy showed that despite there being 
some positive videos about human papillomavirus (HPV) 
onYouTube, the ones conveying negative messages are 
the most engaging, most watched andreceive the most 
“likes.”14 Additionally, emotionally charged content 
tending to be sharedmore often and more quickly 
compared to neutral ones.15
Stress- related events following immunisation, particu-
larly those that occur in clusters—affecting from a few 
to over 800 individuals, have adversely affected immuni-
sation programmes in both developed and low/middle- 
income countries.2
Doubts and uncertainty about vaccine have led to 
somatic reactions in different settings. Clusters of immu-
nisation stress- related responses following immunisation 
have been registered in countries such as Denmark, 
Japan, Pakistan and Colombia. These clusters of reactions 
following vaccination, besides being disruptive to immu-
nisation programmes, can impact overall public trust in 
immunisation and negatively affect vaccine coverage. 
Typically, emotional contagion has been studied within 
small face- to- face networks, however, it is argued that 
physical proximity may not be necessary and that images, 
video and even text- based communication across social 
media can provoke the spread of emotional states.16
In 2013, Colombia had one of the highest HPV immu-
nisation rates in the Americas, at over 90%. In May 2014, 
after routine HPV immunisation at a school in the rural 
area of Carmen de Bolivar, a group of 15 girls from the 
same school were admitted to the hospital presenting 
symptoms of tachycardia, shortness of breath and numb-
ness of limbs. Following media coverage of the cases and 
videos uploaded online, symptoms spread to other cities 
in Colombia affecting over 500 girls. The Colombian 
Institute of Health conducted an epidemiological investi-
gation of the girls affected, but no organic link was found 
between HPV immunisation and reported symptoms. 
Nonetheless, the events affected public confidence and 
HPV immunisation coverage in Colombia dropped to as 
low as 17.5% in 2016.17
These types of reactions are not unique to HPV vaccina-
tion. One single incident in Pakistan during a polio mass 
immunisation campaign in 2019 caused mass contagion, 
and hundreds of children were rushed to hospital with 
complaints of abdominal pain, vomiting and fainting 
following polio vaccination, triggering angry protesters 
to burn down a healthcare facility.18
Such phenomena, also reported in the literature as 
mass sociogenic illness or mass psychogenic illness, 
consists of physical symptoms involving otherwise healthy 
people. Incidents usually start after exposure to a trigger 
(real or perceived), rumour or observing someone else 
becoming ill. Symptoms are subjective and vary within 
individuals and between episodes, but can include head-
ache, dizziness, nausea, motor impairment, syncope and 
fatigue.19 20
Doctors struggle with the concept of psychogenic 
nature of symptoms as much as the patients do, at times 
giving organic diagnosis such as postural orthostatic 
tachycardia syndrome (POTS), chronic fatigue syndrome 
(CFS) or myalgic encephalomyelitis. Health providers 
should be able to recognise anxiety related or psychoso-
matic symptoms and distinguish those from other condi-
tions to avoid potentially harmful clinical interventions 
which might exacerbate symptoms.
Events such as complex regional pain syndrome, POTS 
and CFS have been reported as AEFIs. With some of 
these conditions, the symptoms and signs remain unex-
plained even after thorough and appropriate medical 
investigations and no causal association to the vaccine 
established.21
While the vaccine may be assessed as having no causal 
link to adverse events, it is now recognised that the 
experience of vaccination can play a role in triggering 
stress- related responses following immunisation. These 
symptoms equally need attention in order to mitigate 
individual as well as public anxiety, and possible disrup-
tions to immunisation programmes.
PREPAREDNESS AND RESPONSE TO ADDRESS ISRR
With the evolving social, cultural, communications and 
media landscape, surrounding vaccination it is impor-
tant to anticipate, prepare for and respond effectively 
to ISRR. Healthcare providers not only need to have the 
knowledge and skills to administer vaccines, but also be 
trained to anticipate and address atypical adverse events 
such as ISRR. A friendly, confident, relaxed approach 
with empathy and supportive communication to build 
trust with the vaccine recipient and caregiver will be key 
to mitigate the occurrence of ISRR.22
Before administering a vaccine, individuals with 
predisposing risk factors such as being in the adolescent 
age group (10–19 years), having a history of vasovagal 
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syncope, previous negative experience of immunisa-
tion, an expressed fear of injections or needles or pre- 
existing conditions such as an anxiety disorder or a 
developmental issue such as autism spectrum disorder 
should be identified, and their special needs addressed 
at the time of vaccination. To respond to clusters of 
ISRR at a programme level, it is important for immu-
nisation programmes and relevant staff have a clear 
pre- established communications strategy to decide if, 
when and what needs to be communicated should ISRR 
occur. When clusters of such events occur, they should 
be thoroughly investigated, causality assessed and stake-
holders—including the media, healthcare providers and 
public—should be kept informed to mitigate the spread 
of unfounded rumours. Monitoring public sentiment 
across social media, if feasible, can be helpful to detect 
and guide emerging misinformation at the nascent phase 
before it spreads.23
At an individual level, the responses to stress due to 
needles (and vaccination) vary from person to person 
or may change according to age, time or context. It can 
manifest with variable severity of symptoms and may 
range from mild feelings of worry and ‘butterflies’ in the 
stomach, increased heart rate, palpitations, difficulty in 
breathing or rapid breathing (hyperventilation), loss of 
consciousness and/or seizures. Thus, the spectrum of an 
ISRR can vary from acute stress response including a vaso-
vagal reaction where the onset of symptoms maybe just 
prior to, during or immediately after vaccination (usually 
within 5 min) or a dissociative neurological symptom 
reaction (with or without non- epileptic seizures) that 
may take hours to days to develop after immunisation. 
Failure to differentiate between the clinical manifesta-
tions of fainting, anxiety and associated hyperventilation 
and other conditions such as anaphylaxis has resulted in 
mismanagement of cases and causing additional avoid-
able harm.24
INNOVATIVE INTERVENTIONS TO BUILD AND SUSTAIN VACCINE 
CONFIDENCE
While social media has amplified fears, anxieties and 
uncertainties, social media has also been successfully 
used to listen to and engage publics. HPV vaccination 
coverage in Denmark dropped dramatically from 79% 
to 17% following fears of adverse events due to episodes 
of ISSR.25 Danish Health authorities, after listening to 
parents, learnt that Facebook was where many of them 
were getting their information about the HPV vaccine. 
Among various social media interventions, they devel-
oped collaboratively with teenage girls, was a social media 
campaign, including a Facebook page to help answer 
parent’s questions and share stories.26
In addition to direct interventions with the public, 
another important initiative is the Vaccine Safety Net 
(VSN) (Coauthor Isabel Sahinovic is the Coordinator of 
the VSN and has authored this section) which is a world-
wide network of websites, verified by WHO, that provide 
reliable information on vaccine safety. The initiative has 
two main goals: to facilitate access to trustworthy and 
science- based information on vaccine safety for internet 
users, and the second goal is to collaborate, as a network, 
with other international initiatives, to increase awareness 
about vaccines and contribute to building confidence in 
vaccines. Newly qualified VSN websites are authorised to 
host a VSN visual identity on their homepage to signal 
to visitors that they are accessing a safe place for trusted 
vaccine information that meets the good information 
practices criteria defined by the GACVS.27
The Network’s greatest asset is the diversity of its 
websites. Trusted information is generated from different 
parts of the world and in multiple languages. This allows 
for culturally sensitive material, tailored to local contexts, 
that takes into consideration the audience’s interests and 
health literacy. The Network comprises websites owned 
by governments, professional associations, academia, 
information platforms, fact- checking websites but also 
popular women magazines, community owned websites, 
from high- income and low- income countries. As at April 
2020, 82 websites, from 36 countries were providing infor-
mation in 26 languages. It is estimated that 2 million new 
users are accessing information made available by VSN 
members every month and that last year, some 72 million 
pages were viewed on VSN websites.
Social media are powerful information and influ-
encing channels, so increasing the VSN Network visibility 
through social media networks has also been crucial. 
Among other projects, the VSN Network is exploring 
the use of artificial intelligence and machine learning to 
continuously improve the delivery of tailored messaging, 
including testing new ways of interacting such as through 
chatbots. VSN members will be involved in the content 
development of a Vaccine Safety chatbot to address most 
common concerns the public has around issues related 
to vaccine safety.
CONCLUSION
Public perceptions and concerns around vaccine safety 
are unlikely to be redressed in a letter or rebuttal to a 
scientific Journal, but by understanding what is driving 
public anxieties and sentiments to better address them. 
In some cases, these concerns may flag an emerging 
new safety concern, in others it may be an issue of good 
science but poor communication, historic distrust in the 
information provider or an ISRR. Whatever the issue, if 
not taken seriously and addressed promptly, perceptions 
of risk will not only persist, but will keep growing—a 
phenomenon risks specialists call ‘the social amplifica-
tion of risk’.”28
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